Shopping Cart 0
Cart Subtotal
USD 0

Aplastic Anemia - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Aplastic Anemia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia-Pipeline Review, H2 2018, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aplastic Anemia-Overview

Aplastic Anemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Aplastic Anemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aplastic Anemia-Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

Cell Source Inc

Cellenkos Inc

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Jiangsu Hengrui Medicine Co Ltd

Regen BioPharma Inc

Aplastic Anemia-Drug Profiles

Anemir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-8040-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Aplastic Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Aplastic Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Hematological Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-0801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CordIn-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXG-34217-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HemaXellerate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hetrombopag Olamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotatercept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aplastic Anemia-Dormant Projects

Aplastic Anemia-Discontinued Products

Aplastic Anemia-Product Development Milestones

Featured News & Press Releases

Jul 31, 2018: Kyowa Hakko Kirin submits application for additional indication for Romiplostim (Recombinant) for aplastic anemia in Japan

Oct 24, 2016: Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, for treatment of Bone Marrow Suppression Study

Sep 22, 2016: Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy

May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate

May 03, 2016: Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients

Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate

Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application

Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate

Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia

Jul 21, 2015: Regen BioPharma Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study

Jul 09, 2015: Regen BioPharma Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study

May 05, 2015: Regen BioPharma presents HemaXellerate at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC

Apr 22, 2015: Regen BioPharma Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Aplastic Anemia, H2 2018 8

Number of Products under Development by Companies, H2 2018 9

Number of Products by Targets, H2 2018 14

Number of Products by Stage and Targets, H2 2018 14

Number of Products by Mechanism of Actions, H2 2018 16

Number of Products by Stage and Mechanism of Actions, H2 2018 16

Number of Products by Routes of Administration, H2 2018 18

Number of Products by Stage and Routes of Administration, H2 2018 18

Number of Products by Molecule Types, H2 2018 20

Number of Products by Stage and Molecule Types, H2 2018 20


List Of Table

List of Tables

Number of Products under Development for Aplastic Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Aplastic Anemia-Pipeline by Acceleron Pharma Inc, H2 2018

Aplastic Anemia-Pipeline by Amgen Inc, H2 2018

Aplastic Anemia-Pipeline by BioLineRx Ltd, H2 2018

Aplastic Anemia-Pipeline by Cell Source Inc, H2 2018

Aplastic Anemia-Pipeline by Cellenkos Inc, H2 2018

Aplastic Anemia-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Aplastic Anemia-Pipeline by Gamida Cell Ltd, H2 2018

Aplastic Anemia-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Aplastic Anemia-Pipeline by Regen BioPharma Inc, H2 2018

Aplastic Anemia-Dormant Projects, H2 2018

Aplastic Anemia-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Aplastic Anemia Therapeutic Products under Development, Key Players in Aplastic Anemia Therapeutics, Aplastic Anemia Pipeline Overview, Aplastic Anemia Pipeline, Aplastic Anemia Pipeline Assessment


Companies

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

Cell Source Inc

Cellenkos Inc

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Jiangsu Hengrui Medicine Co Ltd

Regen BioPharma Inc

Aplastic Anemia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia-Pipeline Review, H2 2018, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aplastic Anemia-Overview

Aplastic Anemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Aplastic Anemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aplastic Anemia-Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

Cell Source Inc

Cellenkos Inc

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Jiangsu Hengrui Medicine Co Ltd

Regen BioPharma Inc

Aplastic Anemia-Drug Profiles

Anemir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-8040-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Aplastic Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Aplastic Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Hematological Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-0801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CordIn-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXG-34217-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HemaXellerate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hetrombopag Olamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotatercept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aplastic Anemia-Dormant Projects

Aplastic Anemia-Discontinued Products

Aplastic Anemia-Product Development Milestones

Featured News & Press Releases

Jul 31, 2018: Kyowa Hakko Kirin submits application for additional indication for Romiplostim (Recombinant) for aplastic anemia in Japan

Oct 24, 2016: Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, for treatment of Bone Marrow Suppression Study

Sep 22, 2016: Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy

May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate

May 03, 2016: Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients

Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate

Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application

Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate

Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia

Jul 21, 2015: Regen BioPharma Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study

Jul 09, 2015: Regen BioPharma Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study

May 05, 2015: Regen BioPharma presents HemaXellerate at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC

Apr 22, 2015: Regen BioPharma Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Aplastic Anemia, H2 2018 8

Number of Products under Development by Companies, H2 2018 9

Number of Products by Targets, H2 2018 14

Number of Products by Stage and Targets, H2 2018 14

Number of Products by Mechanism of Actions, H2 2018 16

Number of Products by Stage and Mechanism of Actions, H2 2018 16

Number of Products by Routes of Administration, H2 2018 18

Number of Products by Stage and Routes of Administration, H2 2018 18

Number of Products by Molecule Types, H2 2018 20

Number of Products by Stage and Molecule Types, H2 2018 20


List Of Table

List of Tables

Number of Products under Development for Aplastic Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Aplastic Anemia-Pipeline by Acceleron Pharma Inc, H2 2018

Aplastic Anemia-Pipeline by Amgen Inc, H2 2018

Aplastic Anemia-Pipeline by BioLineRx Ltd, H2 2018

Aplastic Anemia-Pipeline by Cell Source Inc, H2 2018

Aplastic Anemia-Pipeline by Cellenkos Inc, H2 2018

Aplastic Anemia-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Aplastic Anemia-Pipeline by Gamida Cell Ltd, H2 2018

Aplastic Anemia-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Aplastic Anemia-Pipeline by Regen BioPharma Inc, H2 2018

Aplastic Anemia-Dormant Projects, H2 2018

Aplastic Anemia-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Aplastic Anemia Therapeutic Products under Development, Key Players in Aplastic Anemia Therapeutics, Aplastic Anemia Pipeline Overview, Aplastic Anemia Pipeline, Aplastic Anemia Pipeline Assessment


Companies

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

Cell Source Inc

Cellenkos Inc

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Jiangsu Hengrui Medicine Co Ltd

Regen BioPharma Inc